{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362262943655979008.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1182/blood-2012-08-447581"}},{"identifier":{"@type":"URI","@value":"http://ashpublications.org/blood/article-pdf/121/20/4166/531013/4166.pdf"}}],"dc:title":[{"@value":"Prognostic impact and targeting of CRM1 in acute myeloid leukemia"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Key Points</jats:title>\n               <jats:p>High CRM1 expression was associated with short survival of AML patients. CRM1 inhibitor KPT-185 induces apoptosis mainly in a p53-dependent manner, whereas inhibition of proliferation was p53 independent.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382262943655979014","@type":"Researcher","foaf:name":[{"@value":"Kensuke Kojima"}],"jpcoar:affiliationName":[{"@value":"Section of Molecular Hematology and Therapy, Department of Leukemia,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979020","@type":"Researcher","foaf:name":[{"@value":"Steven M. Kornblau"}],"jpcoar:affiliationName":[{"@value":"Section of Molecular Hematology and Therapy, Department of Leukemia,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979013","@type":"Researcher","foaf:name":[{"@value":"Vivian Ruvolo"}],"jpcoar:affiliationName":[{"@value":"Section of Molecular Hematology and Therapy, Department of Leukemia,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979015","@type":"Researcher","foaf:name":[{"@value":"Archana Dilip"}],"jpcoar:affiliationName":[{"@value":"Section of Molecular Hematology and Therapy, Department of Leukemia,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979021","@type":"Researcher","foaf:name":[{"@value":"Seshagiri Duvvuri"}],"jpcoar:affiliationName":[{"@value":"Section of Molecular Hematology and Therapy, Department of Leukemia,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979008","@type":"Researcher","foaf:name":[{"@value":"R. Eric Davis"}],"jpcoar:affiliationName":[{"@value":"Department of Lymphoma and Myeloma,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979023","@type":"Researcher","foaf:name":[{"@value":"Min Zhang"}],"jpcoar:affiliationName":[{"@value":"Department of Lymphoma and Myeloma,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979016","@type":"Researcher","foaf:name":[{"@value":"Zhiqiang Wang"}],"jpcoar:affiliationName":[{"@value":"Department of Lymphoma and Myeloma,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979010","@type":"Researcher","foaf:name":[{"@value":"Kevin R. Coombes"}],"jpcoar:affiliationName":[{"@value":"Department of Bioinformatics and Computational Biology, and"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979017","@type":"Researcher","foaf:name":[{"@value":"Nianxiang Zhang"}],"jpcoar:affiliationName":[{"@value":"Department of Bioinformatics and Computational Biology, and"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979012","@type":"Researcher","foaf:name":[{"@value":"Yi Hua Qiu"}],"jpcoar:affiliationName":[{"@value":"Section of Molecular Hematology and Therapy, Department of Leukemia,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979009","@type":"Researcher","foaf:name":[{"@value":"Jared K. Burks"}],"jpcoar:affiliationName":[{"@value":"Section of Molecular Hematology and Therapy, Department of Leukemia,"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979019","@type":"Researcher","foaf:name":[{"@value":"Hagop Kantarjian"}],"jpcoar:affiliationName":[{"@value":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979011","@type":"Researcher","foaf:name":[{"@value":"Sharon Shacham"}],"jpcoar:affiliationName":[{"@value":"Karyopharm Therapeutics, Boston, MA"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979018","@type":"Researcher","foaf:name":[{"@value":"Michael Kauffman"}],"jpcoar:affiliationName":[{"@value":"Karyopharm Therapeutics, Boston, MA"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943655979022","@type":"Researcher","foaf:name":[{"@value":"Michael Andreeff"}],"jpcoar:affiliationName":[{"@value":"Section of Molecular Hematology and Therapy, Department of Leukemia,"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00064971"},{"@type":"EISSN","@value":"15280020"}],"prism:publicationName":[{"@value":"Blood"}],"dc:publisher":[{"@value":"American Society of Hematology"}],"prism:publicationDate":"2013-05-16","prism:volume":"121","prism:number":"20","prism:startingPage":"4166","prism:endingPage":"4174"},"reviewed":"false","url":[{"@id":"http://ashpublications.org/blood/article-pdf/121/20/4166/531013/4166.pdf"}],"createdAt":"2013-04-06","modifiedAt":"2019-11-16","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002216114936704","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002218685016704","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232143138048","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pharmacological activation of wild-type p53 in the therapy of leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235487900672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Induction of p53‐mediated transcription and apoptosis by exportin‐1 (<scp>XPO</scp>1) inhibition in mantle cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004238270996096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021390757889920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Enhanced\n            <i>TP53</i>\n            reactivation disrupts\n            <i>MYC</i>\n            transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693932242048","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710465172736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Preclinical activity of the novel B‐cell‐specific Moloney murine leukemia virus integration site 1 inhibitor <scp>PTC</scp>‐209 in acute myeloid leukemia: Implications for leukemia therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285712553937664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285713249820800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905610656896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565166738624768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565169416542336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567187531567488","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567188225104512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567188227634944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643381462144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1361131417058624256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1182/blood-2012-08-447581"},{"@type":"CROSSREF","@value":"10.1111/cas.12430_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1016/j.exphem.2016.05.014_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1126/sciadv.adh1436_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1182/blood-2015-05-646240_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1111/cas.12833_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0137210_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.25558_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1158/1078-0432.ccr-15-0481_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1093/neuonc/noae280_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1038/bcj.2017.8_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0139254_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0138377_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.7667_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1016/j.neo.2019.06.001_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1126/scisignal.aac4380_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.1016/j.pharmthera.2015.06.001_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.16602_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.11904_references_DOI_535k8c5xWtVxJ7yVISTsa035Vg2"}]}